Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

Chemotherapy as one of the basic modalities of oncology treatment often leaves permanent implications and among the most common is infertility as a result of irreversible gonadal damage. This project sets the primary target to verify the protective effect GnRH analogues administration to protect ovarian tissue during three different regimens of chemotherapy in patients with Hodgkin disease (HD) in reproductive age.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Masaryk University
• Collaborator: Ministry of Health, Czech Republic
• Treatments: Triptorelin Pamoate

Criteria

Inclusion Criteria:

• diagnosis of Hodgkin lymphoma

• FSH and LH levels in peripheral blood below 15 IU/l

• fertile age from 18 to 35 years

• female

• presence of both ovaries

Exclusion Criteria:

• ovarian tumours or cysts over 40 mm in diameter